Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following are excluded:
• •Prior Pneumocystis carinii pneumonia (PCP) or AIDS-defining condition.
• •Prophylaxis for PCP in preceding 3 months.
• •Absence of detectable glucose-6-phosphate dehydrogenase (G6PD) activity.
• •Prior type I hypersensitivity (anaphylaxis, urticaria, angioedema) or exfoliative dermatitis during treatment with dapsone.
• •History of poor compliance.
• •Concurrent Medication:
• •Excluded:
• •Zidovudine (AZT).
• •Patients with the following are excluded:
• •Prior Pneumocystis carinii pneumonia (PCP) or AIDS-defining condition.
• •Prophylaxis for PCP in preceding 3 months.
• •Absence of detectable glucose-6-phosphate dehydrogenase (G6PD) activity.
• •Concurrent or prior therapy with zidovudine (AZT).
• •Prior type I hypersensitivity (anaphylaxis, urticaria, angioedema) or exfoliative dermatitis during treatment with dapsone.
• •History of poor compliance.
• •Prior Medication:
• •Excluded:
• •Zidovudine (AZT).